Aim of the study: We investigated the biochemical and physiological mechanisms of action of phentolamine mesylate (Vasomax TM ) in regulating erectile tissue smooth muscle contractility in human and rabbit corpus cavernosum. Methods: The binding activity of phentolamine was investigated in a cell-free system by displacement of speci®c and selective radiolabelled ligands to alpha 1 and 2 adrenergic receptors. The physiologic activity of phentolamine-mediated relaxation of adrenergic and non-adrenergic pre-contracted erectile tissue strips of human and rabbit corpus cavernosum were studied in organ bath chambers. 
Introduction
Phentolamine mesylate, an adrenergic antagonist, has been marketed as an injectable substance (Regitine, Ciba-Geigy) for over 40 y in the United States. It is approved for the treatment of pheochromocytoma-related hypertension, for the diagnosis of pheochromocytoma and for norepinephrine-related dermal necrosis. Since 1984, phentolamine mesylate has also been successfully utilized, in combination with other vasoactive agents, for the intracavernosal pharmacological treatment of male erectile dysfunction. 1 Due to inherent problems with self-injection therapy as treatment for male erectile dysfunction, Zorgniotti, 2 Gwinup 3 and Wagner et al 4 have utilized oral and buccal formulations of phentolamine mesylate in pilot studies.
A new formulation of oral phentolamine mesylate (Vasomax TM ) is currently being investigated for its safety and ef®cacy in the treatment of male erectile dysfunction. 5±8 Pharmacokinetic studies in normal volunteers have revealed that the mean phentolamine plasma concentration, 30 min after oral ingestion of 40 mg Vasomax TM tablets, was 16 ng/ml (42± 50 nM). 9 Recent double-blind, placebo controlled, multi-institutional clinical trials with Vasomax TM have documented signi®cant improvement in erectile function compared to placebo in patients with minimal erectile dysfunction.
5±8
The molecular mechanisms of action underlying phentolamine mesylate-induced improvement of erectile function are thought to be exclusively related to local inhibition of post-synaptic alpha-adrenergic receptors, however, local actions of phentolamine in vascular smooth muscle may also include non-adrenergic pathways. 10 The aim of this study was to detail, for the ®rst time, the biochemical and physiological mechanisms of action of phentolamine mesylate-mediated relaxation of corpus cavernosum by adrenergic and non-adrenergic mechanisms.
Materials and methods

Tissue procurement
To examine the biochemical and physiological mechanisms of action of phentolamine mesylatemediated relaxation, both human and rabbit corpus cavernosum erectile tissues were utilized, as indicated in the legend to the speci®c experiments. In general, initial experiments were performed with erectile tissue from the New Zealand White male rabbit. The methodology of tissue harvest was approved by the Institutional Animal Care Committee and has been previously reported. 11, 12 Data concerning phentolamine mesylate-mediated activity in rabbit erectile tissue were then con®rmed using human erectile tissue. Human corpus cavernosum erectile tissues were procured during penile prosthesis implantation as approved by the Institutional Review Board for Human Studies. In the operating room, erectile tissue biopsies were placed in chilled physiological salt solution and immediately transported to the laboratory for experimentation as previously reported. 11, 12 Radioisotopes and chemicals 
Biochemical binding studies
Membrane preparation and phentolamine mesylate binding to alpha 1 and 2 adrenergic receptors in corpus cavernosum smooth muscle were carried out as described previously. 12±14 The data represents the cumulative observations from two or more independent experiments.
Physiological studies in organ bath chambers
Human and rabbit corpus cavernosum strips were mounted to force transducers (Grass Instruments FT03, Quincy, MA) in 25 ml organ baths (37 C) containing Krebs solution and aerated with 5% CO 2 / 95% air to maintain a pH of 7.4. Optimal isometric tension for contraction was attained as described previously. 11, 13, 14 The maximum contraction induced by 80 mM KCl was determined for each strip before starting the experimental protocols. Dose responses to various adrenergic agonists were obtained by cumulative additions of drugs to the chambers in half log increments starting at 1 nM and continuing until the maximal contraction was achieved with each treatment. For relaxation studies, tissues were precontracted with a submaximal concentration of phenylephrine (1 mM), KCl (20± 40 mM) or endothelin (30 nM). Once stable contraction was reached, phentolamine dose responses were initiated by the addition of drug in half log increments (0.1 nM±0.1 mM). At the end of the experiment, 100 mM papaverine was added to determine maximal relaxation. In experiments in which the strips were pre-contracted with KCl, bretylium (10 mM), guanethidine (10 mM) and propranolol (1 mM) were added to inhibit KCl-induced norepinephrine release. 11, 13 Relaxation data were normalized as a percent of 80 mM KCl contraction for each concentration.
Statistical analysis
Relaxation of corpus cavernosum tissue to various drugs is expressed as the percent change in tone. Maximum tone of the tissue is de®ned as that tone between the contraction to phenylephrine (1 mM) and the relaxation induced by papaverine (100 mM). Analysis of variance (ANOVA) was used to compare the responses between control and phentolamine. (Figure 4) .
Effects of phentolamine on alpha 1 adrenergic receptor mediated responses
Phenylephrine elicited concentration-dependent contractions in rabbit corpus cavernosum. Phentolamine mesylate in concentrations ranging from 1 nM± 10 mM displaced the phenylephrine contractile response to the right (Figure 5a and 5b) . In human erectile tissues, phentolamine caused dose-dependent relaxation in strips precontracted with 3 mM phenylephrine; the half-maximal relaxation response (EC 50 ) occurred at 10±30 nM phentolamine, and the maximal relaxation response at 1 mM (Figure 6a ). 
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Phentolamine caused dose-dependent relaxation in strips pre-contracted with 1 mM phenylephrine, 5 mM norepinephrine and 1 uM oxymetazoline (Figure 6b ).
Effects of phentolamine on alpha 2 adrenergic receptor mediated responses
The alpha 2 adrenergic receptor agonist, UK 14 304, caused concentration-dependent contraction in rabbit and human corpus cavernosum. Phentolamine mesylate in concentrations ranging from 10 nM± 1 mM displaced the UK 14 304 contractile response to the right (Figure 7a and 7b) . Phentolamine caused dose-dependent relaxation in strips precontracted with 3 or 10 mM UK 14 304 (Figure 8 ). In human erectile tissues precontracted with 3 mM UK 14 304, the half-maximal relaxation response (EC 50 ) occurred at 30±50 nM phentolamine, and the maximal relaxation response occurred at 1 mM (Figure 6a ).
Effects of phentolamine on KCl and endothelin-1 precontracted corpus cavernosum
In rabbit corpus cavernosum strips precontracted with 80 mM KCl or 30 nM endothelin-1, phentolamine mesylate caused concentration-dependent relaxation (Figures 9 and 10 ). Since the mechanisms of contraction induced by KCl or endothelin-1 are not mediated by alpha-adrenergic receptors, an additional non-adrenergic mechanism for phentolamine-induced corpus cavernosum relaxation was suspected. rabbit corpus cavernosum strips, in organ chambers were treated with phenylephrine to determine maximal contractions. Strips were then washed and exposed to various concentrations of phentolamine for 30 min and then subjected to phenylephrine to determine maximal contractions. All data were normalized as described in Methods (for each dose response, n 3±6 experiments). To examine if phentolamine mesylate mediated its non-adrenergic relaxation activity via a nitric oxide pathway, rabbit corpus cavernosum strips were precontracted with 80 mM KCl with or without the reversible nitric oxide synthase inhibitor, Lnitroarginine (LNNA, 30 mM). In the presence of LNNA, the phentolamine mesylate-induced relaxation response was shifted to the right (Figure 9) . Similarly, the relaxation response of corpus cavernosum strips precontracted with 30 nM endothelin-1 was reduced in the presence of LNNA (30 mM) (Figure 10 ). In addition, phentolamine induced relaxation was reduced in corpus cavernosum strips in which the endothelium was removed and were pre-contracted with 1 mM phenylephrine (data not shown).
Discussion
Phentolamine mesylate is under clinical trials testing for potential use as an oral agent in the treatment of erectile dysfunction. 5±8 The mechanism of action of phentolamine in regulating corpus Figure 7 Effects of phentolamine on alpha 2 adrenergic receptor mediated responses. (a) Human corpus cavernosum strips or (b) rabbit corpus cavernosum strips, in organ chambers were treated with phenylephrine to determine maximal contractions. Strips were then washed and exposed to various concentrations of phentolamine for 30 min and then subjected to UK 14 304 to determine maximal contractions. All data were normalized as described in Methods. For each dose response, n 4±8 experiments. 
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In this study, we demonstrated that phentolamine mesylate was an effective alpha 1 and alpha 2 adrenergic receptor blocker in both rabbit and human corpus cavernosum erectile tissue. Phentolamine competitively displaced speci®c alpha 1 receptor ligands (HEAT and prazosin) and speci®c alpha 2 receptor ligands (rauwolscine and RX 821002). The af®nity of phentolamine for alpha 1 adrenergic receptors was comparable to the alpha 1A selective receptor antagonist 5-methylurapidil but was less than that of prazosin. The af®nity of phentolamine for the alpha 2 adrenergic receptors was greater than that of the alpha 2 receptor agonist UK 13 304 and norepinephrine but was less than that of the alpha 2 receptor antagonists delequamine (RS 1385-197) and rauwolscine. The relatively high af®nity of binding of phentolamine mesylate to alpha 1 and 2 adrenergic receptors suggests that, 30 min following oral ingestion of 40 mg of Vasomax TM , the mean plasma phentolamine concentrations (42±50 nM) will suf®ciently occupy the alpha adrenergic receptors in corpus cavernosum erectile tissue resulting in inhibition of adrenergic-mediated physiologic activity.
In rabbit and human corpus cavernosum erectile tissue, phentolamine mesylate shifted the dose response of phenylephrine (selective alpha 1-mediated) and UK-14 304 (selective alpha 2-mediated) contraction in a concentration-dependent manner. Phentolamine mesylate also induced concentration dependent relaxation in erectile tissue pre-contracted with the selective alpha 1 receptor agonists phenylephrine and oxymetazoline, the selective alpha 2 receptor agonist UK 14 304 and the non-selective agonist norepinephrine. These data indicate that phentolamine alpha-adrenergic binding activity mediates the physiologic inhibition of adrenergic-induced corpus cavernosum contractile tone and the resulting relaxation response.
Contractile responses mediated by 80 mM KCl are thought to occur by electromechanical coupling via depolarization of the corpus cavernosum smooth muscle primarily by activation of L-type calcium channels and calcium in¯ux. 15 Endothelin-induced contractions are thought to occur via receptor mediated intracellular calcium release. 12 Both of these contractile responses are mediated by nonadrenergic mechanisms. Phentolamine mesylateinduced relaxation of corpus cavernosum strips pre-contracted with 80 mM KCl or endothelin suggest that phentolamine mediates corpus cavernosum tissue contractility by both adrenergic and nonadrenergic pathways.
One likely possibility to explain phentolamine mesylate-induced relaxation of KCl contracted tissue was inhibition of calcium entry via L-type calcium channels by phentolamine. While nitripdine effectively competed for binding of PN 200-110 in human corpus cavernosum membranes, phentolamine did not, suggesting that phentolamine mesylate was not acting as L-type calcium channel blocker.
Another possibility was that phentolamine acted as an indirect antagonist, in that, phentolamine demonstrated activity at a second receptor site, eliciting responses which antagonized the electromechanical (KCl) or pharmaco-mechanical coupling (endothelin). Indirect antagonism is a recognized complementary pharmacological mechansim of action of many natural and synthetic agonists and antagonists. In this study, we found that phentolamine mesylate caused concentration dependent relaxation of erectile tissue strips pre-contracted with KCl or endothelin. This relaxation response was attenuated by the competitive nitric oxide synthase inhibitor, L-nitroarginine, and by the mechanical disruption of the endothelium. Such data suggest that phentolamine mesylate-mediated relaxation in corpus cavernosum erectile tissue occurred via an additional non-adrenergic, endothelial-based, nitric-oxide mechanism.
Phentolamine mesylate is an adrenergic antagonist to the contractile substance norepinephrine. Phentolamine was found to also possess the agonist function of tissue relaxation via endothelial nitric oxide pathways. In erectile tissue, phentolamine thus was found to elicit activity via a dual mechanism of action. One pathway was by direct antagonism of alpha 1 and alpha 2 receptor agonists, at the receptor level, resulting in reduced intracellular calcium release and inhibition of contractility. The other mechanism was probably by an indirect, functional antagonism, in which phentolamine Phentolamine mesylate in penile erection A Traish et al bound to an as yet unidenti®ed receptor on the endothelium and activated nitric oxide synthase. This additional pathway may be responsible for corporal smooth muscle relaxation (Figure 11 ).
Identi®cation of a dual mechanism of phentolamine-induced corpus cavernosum relaxation implies that novel combinations of pharmacologic agents with alternative mechanisms of corporal smooth muscle relaxation may be employed in patients with erectile dysfunction unable to restore functional erections with single oral pharmacological agents. For example, selective phosphodiesterase inhibitors are also being developed for the treatment of male erectile dysfunction. 16 Such agents alter intracellular cyclic nucleotide levels by diminishing cyclic nucleotide metabolism. 16 Phentolamine, which has been found in erectile tissue to inhibit adrenergic receptors and increase cyclic nucleotide levels by enhancing nitric oxide synthase, may be theoretically utilized in conjunction with selective phosphodiesterases to improve therapeutic responses in selected patients.
Conclusions
In summary, a new formulation of phentolamine mesylate is being developed as an oral agent in the treatment of male erectile dysfunction. Phentolamine mesylate has been found to modulate human and rabbit corpus cavernosum smooth muscle contractility by direct alpha 1 and alpha 2 adrenergic receptor antagonism. The concentration of phentolamine required to displacing half maximal binding or to produce half-maximal relaxation was Figure 11 Hypothetical mechanism of action of phentolamine-induced relaxation of corpus cavernosum smooth muscle. Phentolamine mesylate inhibits alpha 1 adrenerigc receptor activity and diminishes the increase in intracellular calcium via reduced levels of inositol trisphosphate. Phentolamine mesylate inhibits alpha 2 adrenergic receptor activity, removing the inhibitory activity of Gi protein allowing for increase in cyclic AMP and decreased intracellular calcium. Phentolamine mesylate also appears to activate nitric oxide synthase and increase cyclic GMP allowing for an increase in cyclic GMP and decreased intracellular calcium.
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A Traish et al similar to that found in plasma 30 min after ingestion of 40 mg of Vasomax TM . Phentolamine mesylate also has been found to have indirect functional antagonism via an endothelium-mediated nitric oxide pathway (Figure 11 ). This latter role of phentolamine suggests that combining oral phentolamine with an oral cyclic GMP-speci®c phosphodiesterase inhibitor will increase cyclic GMP more than either agent alone.
